Trending tickers: latest investor updates on TripAdvisor, Bitmine, WolfSpeed, BYD and AstraZeneca
Starboard Value, an investment firm run by Jeff Smith, has a stake valued at around $160m (£117m), which would make it one of the top shareholders in the company.
Tripadvisor (TRIP) shares have been flat since the start of the year after plunging more than 30% in 2024. Last year, the travel review and booking company said it created a special committee to explore potential options.
Read more: FTSE 100 LIVE: Markets down as Trump's controversial tax bill passes, tariff worries persist
Starboard Value has gained a reputation for pushing for changes such as new CEOs and cost cuts by acquiring significant shares in companies. The firm has pushed for changes at pharmaceutical company Pfizer (PFE) and design-software maker Autodesk (ADSK).
Bitcoin miner Bitmine (BMNR) lost over 10% in after hours trading after surging by 130% in the previous session as it revealed a $250m private placement offering to fund an Ethereum (ETH-USD) treasury strategy.
Thomas Lee, chairman of Bitmine (BMNR), said that stablecoins are 'the 'ChatGPT' of crypto' and that he expects ether (ETH-USD) to appreciate thanks to their adoption. 'Ethereum is the blockchain where the majority of stablecoin payments are transacted […] and thus, ETH should benefit from this growth,' he said.
Until this month, the firm's treasury strategy focused on accumulating bitcoin (BTC-USD).
News that Wall Street strategist Tom Lee is joining Bitmine (BMNR) in a push to make Ethereum's ether (ETH-USD) token central to Bitmine's crypto holdings has helped kick off a massive rally for the stock. The company's share price is up roughly 2,450% over the last week.
Shares in Wolfspeed (WOLF) fell in after hours trading on Friday, pulling back after a surge of more than 50% following the semiconductor company's unexpected Chapter 11 bankruptcy filing, a move that is typically interpreted as a sign of financial distress.
The market reaction stood in stark contrast to the usual response to insolvency announcements. Analysts said the sharp rally likely reflected a combination of speculative interest and investor optimism over the company's restructuring plan.
Rather than signalling a collapse, Wolfspeed's (WOLF) bankruptcy filing is being framed by management as a strategic reset. The creditor-backed plan will reduce the company's debt by $4.6bn and cut annual interest expenses by 60%, according to the firm.
Read more: The most popular stocks and funds investors bought in June
With over 97% of senior secured noteholders already on board, Wolfspeed (WOLF) said it expects to emerge from bankruptcy by the end of the third quarter with $1.3bn in liquidity to support its operations.
Investors are betting that the leaner capital structure will allow the NYSE-listed group to refocus on its core silicon carbide business, a key component in electric vehicles and next-generation power electronics, and eventually restore its competitive position in the market.
Shares in BYD (BYD) slipped in Hong Kong trading on Friday, as investors digested reports that Beijing may be preparing to intervene in the intensifying price war that has gripped China's electric vehicle (EV) sector.
The world's largest EV maker reported a 31% increase in sales for the first half of the year, delivering 2.1 million vehicles, according to a filing with the Hong Kong Stock Exchange. Nearly half of those were pure electric models, with the remainder made up of plug-in hybrids. The company stopped producing internal combustion engine vehicles in 2022.
Despite the strong headline figures, pressure on margins has grown. BYD (BYD) came under criticism in late May after launching another round of price cuts, prompting several rivals to follow suit. In a thinly veiled rebuke, the chairman of Great Wall Motors warned that the sector 'could come under threat if it continues on the same trajectory'.
Read more: Key investing trends in June, from defence stocks to Tesla's sales slump
The China Association of Automobile Manufacturers has also weighed in, urging fair competition and healthy development of the industry, and noting that major discounts by a single automaker had triggered a new price war panic.
Investors appeared to interpret the comments as a signal that authorities may take a more active role in calming the market, potentially through new regulation or coordinated guidance.
Shares in AstraZeneca (AZN.L) edged lower in London on Friday, despite the drugmaker securing a significant regulatory milestone for its cancer portfolio.
The European Commission has approved Imfinzi for use before and after surgery in patients with muscle-invasive bladder cancer, making it the first immunotherapy cleared for this indication in Europe. The approval follows clinical trial results showing the drug reduced the risk of recurrence by 32% and cut the risk of death by 25%. After two years, 82% of patients treated with Imfinzi were still alive.
Michiel Van der Heijden, who led the research, said this approach could be a game changer, as nearly half of patients normally see their cancer return even after chemo and surgery.
Despite the positive data, AstraZeneca (AZN.L) shares have come under pressure in recent days amid reports that chief executive Pascal Soriot has privately floated the idea of relocating the company's headquarters to the US. AstraZeneca, the UK's most valuable listed company, has long criticised the domestic investment climate.
In January, it scrapped plans to invest £450m in a vaccine manufacturing facility in northern England, citing a reduction in government support. A move to shift its primary listing overseas would be a fresh blow to the London Stock Exchange (LSEG.L), which has struggled to retain several high-profile companies in the face of transatlantic valuation gaps.
This Friday, US markets are closed for the Independence Day holiday.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
39 minutes ago
- Yahoo
Deutsche Bank Says PepsiCo (PEP) Needs to Win Investor Confidence
PepsiCo, Inc. (NASDAQ:PEP) is one of the . On June 27, Deutsche Bank released a note regarding PepsiCo, Inc. (NASDAQ:PEP), highlighting that the company needs to win investor confidence as its current strategy is under question due to dropping snack consumption trends in the US. PepsiCo, Inc. (NASDAQ:PEP) is set to release its Q2 2025 results on July 17. Deutsche Bank analyst Steve Powers noted that with the earnings call approaching, the company needs to show some increased sense of urgency to gain investor confidence. He added that although the bank continues to believe that the intrinsic value of PepsiCo, Inc. (NASDAQ:PEP) exceeds its current trading value, the declining consumption trends in the US have disappointed the bull case for the company. A close up of a glass of a refreshing carbonated beverage illustrating the company's different beverages. Powers noted that the upcoming earnings call will be important for the company as it should point to some meaningful conversation regarding how the future will be different from the past. While we acknowledge the potential of PEP as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Sign in to access your portfolio
Yahoo
39 minutes ago
- Yahoo
Merck & Co (MRK) Announces the Approval of ENFLONSIA
Merck & Co., Inc. (NYSE:MRK) is one of the 11 Best 52-Week Low Stocks to Buy Right Now. On June 26, Merck & Co., Inc. (NYSE:MRK) announced that the Advisory Committee on Immunization Practices has approved ENFLONSIA for preventing respiratory syncytial virus in infants younger than 8 months. The recommendation is provisional and is pending the final approval of the CDC Director or the Health and Human Services Secretary. Merck & Co., Inc. (NYSE:MRK) noted that ENFLONSIA is the first and only RSV preventive option administered to infants using the same dose regardless of weight, simplifying dosing logistics. Moreover, earlier this month, the FDA approved ENFLONSIA based on the strong clinical trial data from the Phase 2b/3 CLEVER and Phase 3 SMART trials. The results showed a 60.5% reduction in medically attended RSV lower respiratory infections and an 84.3% reduction in RSV-associated hospitalizations. A close-up of a person's hand holding a bottle of pharmaceuticals. Merck & Co., Inc. (NYSE:MRK) is a global healthcare company that operates through two main business segments including the Pharmaceuticals and Animal Health Segments. It is known for Keytruda and Gardasil, which are the main sources of the company's revenue. While we acknowledge the potential of MRK as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
39 minutes ago
- Yahoo
The Procter & Gamble Company (PG) Is Expected to Cut 7,000 Jobs Over the Next 2 Years
The Procter & Gamble Company (NYSE:PG) is one of the . On June 5, Reuters reported that The Procter & Gamble Company (NYSE:PG) is expected to cut 7,000 jobs over the next two years. This comes as a response to the challenges from the uncertain spending environment in the United States due to the tariffs. The Procter & Gamble Company (NYSE:PG) is also expected to exit some product categories and brands, with anticipated divestitures in certain markets. The job cut of 7,000 represents around 6% of its total workforce. Management has characterized it as part of its ongoing strategy and two-year restructuring program. A happy couple viewing the products of this household and personal product company in a mass merchandiser store. The Procter & Gamble Company (NYSE:PG) is a leading global consumer company that provides branded daily life products. The company operates through five main segments which include Beauty, Grooming, Health Care, Fabric and Home Care, and Baby, Feminine, and Family Care. While we acknowledge the potential of PG as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None.